CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at 10- and ...

SIRPα immunotherapy include targeting overexpressed CD47 in cancers to boost macrophage activity, using dual function molecules to enhance efficacy, and innovative drug designs reducing red blood cell ...

A new study from the USC Norris Comprehensive Cancer Center has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal ...

Mechanism of Action and Novelty of HCB101: An Innovative Fusion Protein Design Developed using HanchorBio's proprietary FBDB™ (Fc-Based Designed Biologics) platform, HCB101 is an engineered SIRPα/CD47 ...

Researchers from the USC Norris Comprehensive Cancer Center and collaborators report that they have found evidence that targeting CD47, a protein that is part of the innate immune system, could be a ...

HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...

Simplified, the CD47 antibody binds to cancer cells, marking them to be eaten by the body's immune cells. Once the immune cells engulf the tumor, the toxin is released inside, becoming activated and ...

Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.

Fosun Pharma subsidiary Henlius Biotech is paying $10 million upfront for regional rights to HanchorBio’s phase 2 CD47 blocker. In return for the rights to develop and commercialize the candidate, ...

NOVEMBER 17, 2025, NEW YORK – Like all hardworking things, the cytotoxic T lymphocytes (CTLs) of the immune system charged with detecting and destroying cancer cells tend to get very tired—so much so, ...